Introduction
The Bombay High Court, in Principal Commissioner of Income Tax vs. M/S. Merck Ltd., delivered a comprehensive judgment on 16th September 2019, addressing multiple contentious issues under the Income Tax Act, 1961, for Assessment Year 2010-11. This appeal under Section 260A challenged the Income Tax Appellate Tribunal (ITAT) order dated 31st March 2016. The Revenue raised five re-framed questions of law concerning transfer pricing adjustments, technical consultancy fees, share buyback expenditure, and sales promotion expenses. The Court dismissed the appeal in its entirety, reinforcing taxpayer-friendly principles on transfer pricing methodologies, expenditure deductibility, and the scope of judicial review under Section 260A. This commentary provides a deep legal analysis of the Court’s reasoning, focusing on the interplay between Rule 10B of the Income Tax Rules, Section 37 of the Act, and the boundaries of substantial questions of law.
Facts of the Case
The respondent, M/S. Merck Ltd., was engaged in manufacturing, trading, and marketing pharmaceuticals. During the relevant assessment year, it imported Bisoprolol Fumarate, an active pharmaceutical ingredient (API), from its Associate Enterprise (AE) in Switzerland. The assessee adopted the Transactional Net Margin Method (TNMM) to determine the Arm’s Length Price (ALP), but the Transfer Pricing Officer (TPO) rejected this and applied the Comparable Uncontrolled Price (CUP) method, determining ALP at Rs. 36,831 per kg against the assessee’s price of Rs. 66,702 per kg, leading to a transfer pricing adjustment of Rs. 1.03 crores. Additionally, the assessee paid Rs. 3 crores to its AE under a technical consultancy agreement, which the TPO valued at Nil. The Assessing Officer also disallowed share buyback expenses as capital expenditure and sales promotion expenses for lack of demonstrated benefit. The ITAT allowed the assessee’s appeals on all counts, prompting the Revenue’s appeal.
Reasoning of the High Court
The Bombay High Court’s reasoning is structured around five distinct legal issues, each analyzed with precision.
1. Transfer Pricing Adjustment and Quality Adjustment under Rule 10B
The Court first addressed the Revenue’s challenge to the ITAT’s grant of a 10% quality adjustment on the ALP of Bisoprolol Fumarate. The Revenue argued that the Tribunal erred in allowing this adjustment without proper justification. However, the Court found no merit in this grievance. It noted that the application of the CUP method was conceded by the assessee, following the binding decision in Serdia Pharmaceuticals India Pvt. Ltd. Vs. ACIT. The core dispute was whether a quality adjustment was permissible under Rule 10B(1)(a)(ii) of the Income Tax Rules, which mandates that the price of a comparable uncontrolled transaction must be “adjusted to account for differences, if any, which could materially affect the price in the open market.”
The Court observed that the TPO himself had allowed a 10% quality adjustment for the same assessee in Assessment Year 2011-12, creating a consistent administrative practice. The Court took judicial notice that even identical products can command different prices in the open market due to perception of quality. Therefore, the ITAT’s decision to allow a 10% adjustment was not only legally sound but also factually supported. The Court emphasized that the Revenue’s challenge did not raise a substantial question of law because the Tribunal’s finding was based on a correct interpretation of Rule 10B and was not perverse. This reasoning underscores the principle that transfer pricing adjustments must account for qualitative differences, and the TPO cannot arbitrarily ignore such factors.
2. Technical Consultancy Fees as Retainer Services
On the issue of technical consultancy fees of Rs. 3 crores paid to the AE, the TPO had determined the ALP at Nil, arguing that no services were actually availed. The ITAT reversed this, holding that the agreement provided a “package of services” on an “as and when required” basis, akin to a retainer agreement. The Bombay High Court upheld this view, relying on its own decision in CIT Vs. Merck Ltd. (Writ Petition No.272 of 2014) for Assessment Year 2003-04, where it held that fees paid for a bouquet of services on a requirement basis have value and cannot be treated as Nil unless the agreement is a sham.
The Court noted that the Revenue conceded that the earlier decision applied to the present facts. This reasoning reinforces the principle that retainer-based service agreements have inherent value, and the TPO cannot disregard them merely because services were not fully utilized. The Court’s reliance on the co-ordinate bench decision in AWB India Ltd. Vs. DCI further solidifies the position that the value of such agreements must be recognized for transfer pricing purposes.
3. Share Buyback Expenditure as Revenue Expenditure
The Revenue argued that share buyback expenditure was capital in nature and not allowable under Section 37. The ITAT had deleted the disallowance, following the Delhi High Court decision in CIT Vs. Selan Exploration Technology Ltd., which held that share buyback does not create an enduring benefit or a new asset; instead, it reduces capital employed. The Bombay High Court agreed, noting that the issue was already concluded by its own decisions in CIT Vs. Aditya Birla Novo Ltd. and CIT Vs. Hindalco Industries Ltd., both decided against the Revenue.
The Court emphasized that the expenditure did not result in the acquisition of any capital asset or enduring benefit. After buyback, the capital employed decreased, and no new asset came into existence. Therefore, the expenditure was revenue in nature and allowable under Section 37. This reasoning aligns with the “no enduring benefit” test, which distinguishes capital from revenue expenditure. The Court’s dismissal of the Revenue’s challenge on this ground reaffirms that share buyback costs are ordinary business expenses.
4. Sales Promotion Expenses and the ‘Wholly and Exclusively’ Test
The Revenue contended that sales promotion and conference expenses should be disallowed because they did not render any benefit to the assessee and were against ethics. The ITAT had allowed these expenses, relying on Supreme Court decisions in CIT Vs. Chandulal Keshavlal & Co. and Sasoon J. David & Co. Vs. CIT, which held that Section 37 requires expenditure to be “wholly and exclusively” for business purposes, not “necessarily” incurred. The Bombay High Court upheld this view, noting that the word “necessity” was deliberately omitted from the Income Tax Act, 1961 after public protest.
The Court observed that it is for the assessee to decide whether expenditure should be incurred in the course of business. Once it is established that the expenditure was incurred wholly and exclusively for business purposes, it is deductible. The Revenue’s argument about lack of benefit was irrelevant because the test under Section 37 is not about demonstrated benefit but about commercial expediency. This reasoning protects taxpayers from subjective assessments by tax authorities and reinforces the principle that business expenditure decisions are best left to the assessee.
5. Non-Adjudication of Issues Not Pressed Before Tribunal
Finally, the Revenue challenged the ITAT’s refusal to adjudicate the disallowance of sales promotion expenses incurred before the amendment to the Indian Medical Council Regulations on 10th December 2009. The ITAT had declined to decide this issue due to the smallness of the amount and because the Revenue did not contest it before the Tribunal. The Bombay High Court held that the Revenue could not raise this issue for the first time in appeal, citing its decision in CIT Vs. Mahalaxmi Glass Works Co., which held that concessions before the Tribunal cannot be challenged later.
The Court’s reasoning on this point is procedural but significant. It reinforces the principle that issues not pressed before the Tribunal cannot be raised in a subsequent appeal under Section 260A. This prevents the Revenue from circumventing lower appellate forums and ensures finality in litigation.
Conclusion
The Bombay High Court’s judgment in PCIT vs. M/S. Merck Ltd. is a landmark decision that provides clarity on several contentious issues in transfer pricing and expenditure allowance. By dismissing all five questions of law, the Court upheld the ITAT’s findings and reinforced key principles: (1) Transfer pricing adjustments must account for qualitative differences under Rule 10B; (2) Retainer-based service agreements have value even if services are not fully utilized; (3) Share buyback expenses are revenue expenditures when they do not create enduring assets; (4) Business expenditure under Section 37 requires only a ‘wholly and exclusively’ purpose, not demonstrated benefit; and (5) Issues not pressed before the Tribunal cannot be raised in appeal. The decision strengthens taxpayer positions on ALP methodologies and expenditure deductibility while curtailing the Revenue’s attempts to revisit factual determinations. It serves as a critical precedent for future transfer pricing and expenditure disputes, emphasizing that the High Court’s jurisdiction under Section 260A is limited to substantial questions of law, not factual re-appreciation.